Videos

Catch up on this week's biggest headlines in FDA news.

Catch up on this week's biggest headlines in FDA news.

This week, the FDA received an application for a metoclopramide nasal spray and a receptor agonist for hypoactive sexual desire disorder, approved baricitinib on its second try, and granted Priority Review to emicizumab for hemophilia A.

This week, the FDA approved the first standalone prosthetic iris, granted priority review to a pediatric anti-epileptic and a postpartum depression drug, accepted another try from an opioid use disorder drug, and announced new plans against the opioid epidemic.

This week on MDNN: Cinnamon flavoring in e-cigarettes has been found to disrupt the lungs’ anti-bacterial defense system, new hypertension guidelines have increased the condition's prevalence, and the US Congress passed a right-to-try bill.

This week on MDNN: ADHD symptoms are linked to binge and restrictive eating, physicians paid by opioid marketers are more likely to prescribe them, and one-third of nurses work overtime.

This week on MDNN: Stigmatizing phrasing influences patient care, Pokemon GO improves behavioral health, depressed women and men differentiate in gene expression, and fast food can stall a woman's time to pregnancy.

This week on MDNN: Autism Spectrum Disorder rates are rising in the US, handwashing is effective for C. diff prevention, and PROMISE 1 trial results have been reported.

This week on MDNN: Prolonged use of acetaminophen has been linked to an increase in the relative risk of ADHD and ASD, the ANA annual meeting issued 30 new recommendations for disease-modifying therapy for multiple sclerosis and the American Academy of Family Physicians announced a new Well-Being Planner to manage stressors and address burnout.

This week on MDNN: The SELECT-COMPARE trial reported positive results for upadacitinib, older adults in the US are not being tested for HIV, and the shifting trends in US mortality.

This week on MDNN: Physician report being unaware of how many opioids they prescribe, legalized marijuana cuts down on opioid rates in Medicaid patients, Grindr responds to leak they share users' HIV statuses, and the FDA recalls salmonella-containing kratom.

This week on MDNN: Neonatal abstinence syndrome increases by 433% over a decade, CDC reports opioid deaths are driven by synthetic strains, and drug use disorder mortality accounts for 4% of all 2015 deaths.

This week on MDNN: America trends toward healthier outcomes, the first-ever gene therapy procedure was performed, and President Donald Trump declared his stance on opioid traffickers.

This week on MDNN: The Minnesota medical cannabis program returns pain management results, Japan university researchers find a new asthma phenotype, and the ACP butts heads with diabetes organizations on blood glucose guidelines.

This week on MDNN: Opioids fare worse for chronic pain, ACP releases new diabetes guidelines, daclizumab is withdrawm from markets, and the FDA makes moves.

Stay updated on the biggest headlines with MDNN from November 24, 2017.

Stay updated on the biggest headlines with MDNN from November 17, 2017.

Stay updated on the biggest headlines with MDNN from November 10, 2017.